[go: up one dir, main page]

MXPA04004609A - Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina. - Google Patents

Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina.

Info

Publication number
MXPA04004609A
MXPA04004609A MXPA04004609A MXPA04004609A MXPA04004609A MX PA04004609 A MXPA04004609 A MX PA04004609A MX PA04004609 A MXPA04004609 A MX PA04004609A MX PA04004609 A MXPA04004609 A MX PA04004609A MX PA04004609 A MXPA04004609 A MX PA04004609A
Authority
MX
Mexico
Prior art keywords
angptl3
angiopoietin
protein
composition
polypeptides
Prior art date
Application number
MXPA04004609A
Other languages
English (en)
Inventor
Eric Sherman Daniel
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MXPA04004609A publication Critical patent/MXPA04004609A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)

Abstract

La presente invencion se dirige a metodos y medios para hacer y utilizar polipeptidos de Angptl3. la invencion especificamente se refiere al uso de polipeptidos de Angptl3 para producir la regeneracion del higado y angiogenesis. Los metodos adicionales incluyen el uso de polipeptidos de Angptl3 en el diagnostico y tratamiento de enfermedad del higado. Tambien se proporcionan en la presente los anticuerpos que se unen a los polipeptidos de la presente invencion.
MXPA04004609A 2001-11-16 2002-11-13 Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina. MXPA04004609A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33242901P 2001-11-16 2001-11-16
PCT/US2002/036865 WO2003044172A2 (en) 2001-11-16 2002-11-13 Composition comprising and method of using angiopoietin-like protein 3 angptl3

Publications (1)

Publication Number Publication Date
MXPA04004609A true MXPA04004609A (es) 2004-08-12

Family

ID=23298191

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04004609A MXPA04004609A (es) 2001-11-16 2002-11-13 Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina.

Country Status (14)

Country Link
US (3) US7267819B2 (es)
EP (1) EP1451578B1 (es)
JP (2) JP5105696B2 (es)
KR (2) KR20100029861A (es)
CN (2) CN101905024A (es)
AU (1) AU2002348286B2 (es)
CA (1) CA2464542C (es)
ES (1) ES2429034T3 (es)
IL (2) IL161542A0 (es)
MX (1) MXPA04004609A (es)
NO (1) NO336021B1 (es)
NZ (1) NZ532852A (es)
WO (1) WO2003044172A2 (es)
ZA (1) ZA200403070B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742075B2 (en) 2006-12-08 2014-06-03 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL3

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
KR20100029861A (ko) 2001-11-16 2010-03-17 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는 조성물 및 이를 사용하는 방법
AU2004266043B2 (en) * 2003-08-21 2007-09-20 Duchesnay Inc. Micronutrient supplement
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
CA2574791A1 (en) 2004-07-20 2006-02-09 Genentech, Inc. Compositions and methods of using angiopoietin-like 4 protein
ZA200701183B (en) * 2004-07-20 2008-05-28 Genentech Inc Inhibitors of angiopoietin-like 4 protein, combinations, an their use
US7807645B2 (en) 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
US8354111B2 (en) 2008-04-14 2013-01-15 Hadasit Medical Research Services And Development Ltd. Stable cell binding chimeric peptides
CN101852805B (zh) * 2009-03-31 2015-04-01 浙江大学 Angptl3作为卵巢癌的诊断标记物的用途
JP5602850B2 (ja) * 2009-07-14 2014-10-08 ザ スクリプス リサーチ インスティテュート 間葉幹細胞分化
AU2015200969A1 (en) * 2010-01-08 2015-03-19 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2011085271A2 (en) * 2010-01-08 2011-07-14 Isis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
WO2011097171A1 (en) * 2010-02-02 2011-08-11 Arizona Board Of Regents Controlled tunnel gap device for sequencing polymers
US20130330752A1 (en) * 2011-01-29 2013-12-12 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AR087329A1 (es) 2011-06-17 2014-03-19 Regeneron Pharma Anticuerpos humanos contra proteina 3 de tipo angiopoietina humana
WO2013110120A1 (en) * 2012-01-24 2013-08-01 Inter-K Pty Limited Peptide agents for cancer therapy
MA38369B1 (fr) 2013-03-08 2018-10-31 Novartis Ag Peptides et compositions pour le traitement d'une lesion de l'articulation
JO3564B1 (ar) * 2013-03-08 2020-07-05 Novartis Ag ببتيدات وتركيبات لعلاج ضرر المفاصل
CN104062432B (zh) * 2013-03-22 2016-01-20 中山大学 ang2在制备ECTC血管类型肝癌诊断试剂及治疗药物中的应用
DK2991656T3 (da) 2013-05-01 2020-03-23 Ionis Pharmaceuticals Inc Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
US20170037409A1 (en) 2013-12-24 2017-02-09 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AU2015252895B2 (en) 2014-05-01 2021-07-15 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
CN105021827B (zh) * 2015-07-17 2016-09-28 北京大学第一医院 检测血清血管生成素样蛋白2含量的物质在制备检测肝脏炎症和纤维化程度产品中的应用
CA2999341A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
CN108779159B (zh) * 2016-02-04 2022-12-30 瑞泽恩制药公司 具有经改造的angptl8基因的非人动物
US20170253666A1 (en) 2016-03-03 2017-09-07 Regeneron Pharmaceuticals, Inc. Methods for Treating Patients with Hyperlipidemia by Administering a PCSK9 Inhibitor in Combination with an ANGPTL3 Inhibitor
US10995335B2 (en) * 2017-09-14 2021-05-04 Arrowhead Pharmaceuticals, Inc. RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use
AR116566A1 (es) 2018-10-03 2021-05-19 Novartis Ag Administración sostenida de polipéptidos similares a la angiopoyetina 3
WO2020099482A2 (en) * 2018-11-13 2020-05-22 Lipigon Pharmaceuticals Ab Angptl 3 oligonucleotides influencing the regulation of the fatty acid metabolism
TWI747098B (zh) * 2018-12-21 2021-11-21 美商美國禮來大藥廠 抗angptl3/8複合物抗體及其使用方法
MX2022000094A (es) * 2019-07-04 2022-04-27 Cadila Healthcare Ltd Vacuna a base de angptl3 para el tratamiento de enfermedad hepática.
CN111122872B (zh) * 2019-11-20 2023-01-20 中山大学附属第一医院 血管生成素样蛋白7在心力衰竭预后评估中的应用
CN110938144B (zh) * 2019-11-27 2022-07-26 复旦大学附属儿科医院 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途
WO2022187353A1 (en) * 2021-03-05 2022-09-09 Anji Pharmaceuticals Inc. Methods and compositions for treating sepsis
CN114934021B (zh) * 2022-04-21 2023-08-08 复旦大学附属儿科医院 一种Angptl3敲除的鼠永生化足细胞系及其应用
CN120254294B (zh) * 2025-06-05 2025-09-09 南昌大学第一附属医院 Angptl3在乙肝相关慢加急性肝衰竭预后中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053757A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO1998037914A1 (en) * 1997-02-26 1998-09-03 Toray Industries, Inc. Remedies for hepatitis
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
WO1999055869A1 (en) * 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
CA2332109A1 (en) * 1998-05-12 1999-11-18 Human Genome Sciences, Inc. 97 human secreted proteins
WO1999067382A2 (en) * 1998-06-24 1999-12-29 Compugen Ltd. Angiopoietin-like growth factor sequences
KR20100029861A (ko) 2001-11-16 2010-03-17 제넨테크, 인크. 안지오포이에틴-유사 단백질 3 ａｎｇｐｔｌ3을 함유하는 조성물 및 이를 사용하는 방법

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8742075B2 (en) 2006-12-08 2014-06-03 Lexicon Pharmaceuticals, Inc. Monoclonal antibodies against ANGPTL3

Also Published As

Publication number Publication date
AU2002348286A1 (en) 2003-06-10
US7267819B2 (en) 2007-09-11
JP2010100624A (ja) 2010-05-06
WO2003044172B1 (en) 2004-03-18
JP5105696B2 (ja) 2012-12-26
CA2464542A1 (en) 2003-05-30
NZ532852A (en) 2006-08-31
CN1615440A (zh) 2005-05-11
WO2003044172A2 (en) 2003-05-30
EP1451578A4 (en) 2006-02-01
EP1451578A2 (en) 2004-09-01
US8541376B2 (en) 2013-09-24
IL161542A0 (en) 2004-09-27
US20030215451A1 (en) 2003-11-20
KR20050044485A (ko) 2005-05-12
NO20042410L (no) 2004-06-09
CN101905024A (zh) 2010-12-08
AU2002348286B2 (en) 2008-04-03
NO336021B1 (no) 2015-04-20
US20090098117A1 (en) 2009-04-16
JP2005521643A (ja) 2005-07-21
US20070134250A1 (en) 2007-06-14
KR101012904B1 (ko) 2011-02-08
EP1451578B1 (en) 2013-08-21
WO2003044172A3 (en) 2003-11-20
ZA200403070B (en) 2005-06-29
CA2464542C (en) 2015-01-20
IL203894A (en) 2013-09-30
KR20100029861A (ko) 2010-03-17
ES2429034T3 (es) 2013-11-12

Similar Documents

Publication Publication Date Title
MXPA04004609A (es) Composicion que comprende y metodo para utilizar angptl3 de proteina 3 como angiopoyetina.
IL161016A0 (en) Specific binding agents of human angiopoietin-2
DE60043197D1 (es)
PL1615952T3 (pl) Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
DE50210317D1 (de) Peptid zur diagnose und therapie der alzheimer-demenz
WO2000040614A3 (en) Characterization of the soc/crac calcium channel protein family
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
WO2001060990A3 (en) Sphingosine kinases
WO2002081625A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2002099062A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
DE69831223D1 (de) Gefriergetrocknete zusammensetzung des menschlichen,morphogenen knochenproteins mp52
WO2002090504A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2005070448A3 (en) Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease
WO2001066740A3 (en) Compositions and methods for the treatment of immune related diseases
WO2002000822A3 (en) A NOVEL POLYPEPTIDE, A HUMAIN PROTEIN SYNTHESIS INITIATION FACTOR SUB-UNIT 2 β 16.5 AND THE POLYNUCLEOTIDE ENCODING THE POLYPEPTIDE
TW200635951A (en) Specific binding agents of human angiopoietin-2
EP1661998A3 (en) Antigenic polypeptides, antibodies binding thereto, nucleic acids encoding the antigens, and methods of use
WO2002072771A3 (en) Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
WO2001096526A3 (fr) Nouveau polypeptide, facteur humain 11.77 d'inhibition tumorale, et polynucleotide codant ce polypeptide
EP1392855A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF VIRAL DISEASES VIA GENE 55092
WO2003034069A3 (en) Tcmp 03 protein for use in cancer therapy
IT1270184B (it) Uso di proteine da schock termico per il trattamento di malattie virali di interesse veterinario
WO2001075010A3 (fr) Nouveau polypeptide, proteine humaine de transduction nucleaire 25 contenant un domaine structurel atp/gtp, et polynucleotide codant pour ce polypeptide
WO2001094533A3 (fr) Nouveau polypeptide, proteine humaine 13 de regulation de la proteine phosphorylase, et polynucleotide codant ce polypeptide
WO2003004618A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use

Legal Events

Date Code Title Description
FG Grant or registration